Literature DB >> 33397240

Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study.

Dipayan Roy1, Purvi Purohit2, Anupama Modi1, Manoj Khokhar1, Ravindra Kumar Gayaprasad Shukla3, Ramkaran Chaudhary4, Shrimanjunath Sankanagoudar1, Praveen Sharma1.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is an ever-growing epidemic in India and poses significant morbidity, mortality, and socioeconomic burden.
INTRODUCTION: Growth differentiation factor-15 (GDF15) is a stress-responsive cytokine, increased in T2DM patients compared to control subjects without the disease. We aimed to assess whether serum GDF15 and adipose tissue GDF15 expression can differentiate between obese pre-diabetes and T2DM and control populations.
METHODOLOGY: We recruited 156 individuals including 73 type 2 diabetes, 30 pre-diabetes, and 53 healthy controls. Clinical history, anthropometric measurements and biochemical profiling were taken. Insulin resistance indices were calculated following HOMA models. Serum GDF15 was measured by sandwich ELISA. Visceral adipose tissue (VAT) expression of GDF15 was observed in 17 T2DM patients and 29 controls using SYBR Green chemistry in RT-PCR using GAPDH as the housekeeping gene. The data were analyzed on R programming platform using RStudio.
RESULTS: Serum GDF15 was significantly higher (p<0.001) in T2DM subjects (median 1445.47 pg/mL) compared to pre-diabetes (627.85 pg/mL) and healthy controls (609.01 pg/mL). Using the ΔΔCt method, the VAT GDF15 expression was 1.54 fold and 1.57 fold upregulated in T2DM (n=17) compared to control subjects (n=29), and obese (n=12) compared to non-obese (n=34)subjects, respectively. The optimal cut-off point following Youden's index method was found to be 868.09 pg/mL. ROC curve analysis revealed that serum GDF15 had a sensitivity, specificity, and area under the curve (AUC) of 90.41%, 79.52%, and 0.892 respectively. GDF15 levels were significantly associated with age, BMI, HbA1c, fasting blood sugar, and insulin resistance indices.
CONCLUSION: Hence, serum GDF15 is a biomarker for T2DM patients in our study population from Western India. However, larger prospective cohorts are necessary to validate this claim. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  GDF15; MIC-1; biomarker; cutpointr; obesity; type 2 diabetes; visceral adipose tissue

Mesh:

Substances:

Year:  2022        PMID: 33397240     DOI: 10.2174/1573399817666210104101739

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  3 in total

Review 1.  Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia.

Authors:  Jawed Akhtar Siddiqui; Ramesh Pothuraju; Parvez Khan; Gunjan Sharma; Sakthivel Muniyan; Parthasarathy Seshacharyulu; Maneesh Jain; Mohd Wasim Nasser; Surinder Kumar Batra
Journal:  Cytokine Growth Factor Rev       Date:  2021-11-17       Impact factor: 7.638

2.  GDF-15 is associated with atherosclerosis in adults with transfusion-dependent beta-thalassemia.

Authors:  Alaa Efat; Rana Wahb; Sabry Abd Allah Shoeib; Ashraf Abd ElRaof Dawod; Mohamad Ahmed Abd ElHafez; Essam Ali Abd ElMohsen; Aly Elkholy
Journal:  EJHaem       Date:  2022-03-22

3.  A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer.

Authors:  Anupama Modi; Purvi Purohit; Ashita Gadwal; Dipayan Roy; Sujoy Fernandes; Jeewan Ram Vishnoi; Puneet Pareek; Poonam Elhence; Sanjeev Misra; Praveen Sharma
Journal:  EJIFCC       Date:  2021-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.